Solid Biosciences Inc.
NASDAQSLDB short interest surges 44.6% in one week to 20.4% of float, driven by gene therapy skepticism over funding runway through mid-2028.
Snapshot as of 19 Jul 2026
Solid Biosciences heads into mid-June with a notable split: short sellers are quietly adding to already-elevated positions, while every analyst covering the stock maintains a bullish rating and targets that sit well…
Solid Biosciences heads into its June 10 earnings report with an unusual split: short interest climbing while the Street grows more bullish. The earnings event is the lens through which everything else reads this week.…
Solid Biosciences heads into its May 19 quarterly report with shorts retreating from a recent peak yet the stock still carrying one of the more elevated short positions in the gene therapy space. Short sellers have…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SLDB — free to start on ORTEX.
Sign up for free →Open SLDB on ORTEX